{"entity":{"id":"nct04864054","kind":"trial","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","aka":["ARYA-3"],"tldr":"A phase 1/2 trial of ECT204 T cells in hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.","summary":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC is a phase 1/2 interventional study registered as NCT04864054 by Eureka Therapeutics Inc., with 60 participants planned, started 2022-03-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: ECT204 T cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04864054","url":"https://clinicaltrials.gov/study/NCT04864054"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc","hcc-advanced"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eureka-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04864054","phase":"1/2","setting":"An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)","sponsor":"Eureka Therapeutics Inc.","started":"2022-03-11","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04864054/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","route":"/companies/eureka-therapeutics/"}]}}